Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2022-10-23 Regulatory Filings
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - VBS 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation (lapse) of certain securities (options) for Vectus Biosystems Limited. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement of changes in the company's issued capital related to securities that have lapsed. It does not contain financial statements, audit information, or detailed financial results. It is not a full report but a regulatory announcement about securities cessation. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-10-23 English
Date of Annual General Meeting 1 page 116.7KB
AGM Information Classification · 95% confidence The document is a short announcement dated 12 October 2022 from Vectus Biosystems Limited regarding the scheduling and format of the 2022 Annual General Meeting (AGM). It mentions the date and time of the AGM, the hybrid meeting format, and instructions for director nominations. There is no detailed financial data, no presentation materials, or voting results included. The document is an announcement about the AGM rather than the AGM materials themselves. Given the short length (1183 characters) and the nature of the content, this fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to the AGM event itself. Therefore, the classification is AGM-R with high confidence.
2022-10-11 English
Change in substantial holding - KHPL 2 pages 637.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001, detailing changes in voting power and relevant interests of a substantial shareholder in Vectus Biosystems Limited. It includes specifics about shareholdings, changes in association, and addresses of relevant parties. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. It is not a financial report, management announcement, or other types of filings. Therefore, the correct classification is Major Shareholding Notification (MRQ).
2022-10-05 English
Change in substantial holding - BS 4 pages 1.1MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and shareholdings of a substantial shareholder, Bernard Stang, including dates and share quantities. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report, but a regulatory notice about shareholding changes.
2022-10-04 English
Change in substantial holding - KD 3 pages 2.5MB
Regulatory Filings
2022-10-03 English
Becoming a substantial holder 3 pages 88.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the substantial shareholding of Regal Funds Management Pty Ltd and its associates in Vectus Biosystems Ltd, including voting power, relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not a financial report, management announcement, or other types of filings. Therefore, the correct classification is MRQ with high confidence.
2022-10-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.